Triple-negative breast cancer trials recruiting in Florida
All Triple-negative breast cancer trials nationally
26
Recruiting in Florida
26
Cities with sites
Cities in Florida
Tampa 10Orlando 8Sarasota 6Jacksonville 4Miami 4St. Petersburg 3Clearwater 2Plantation 2Stuart 2Altamonte Springs 1Boca Raton 1Fort Myers 1
Recruiting trials in Florida
- A Beta-only IL-2 ImmunoTherapY Study
- A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
- A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
- A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
- A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
- A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
- A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- A Study of LY4175408 in Participants With Advanced Cancer
- A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
- DecipHER Trial - DC1 Tx for Early-Stage TNBC and ER Low Positive Breast Cancer
- Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease
- MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
- PRE-ISPY Phase I/II Oncology Platform Program
- Personalized Dendritic Cell Vaccine Pilot for High Risk TNBC After Neoadjuvant Therapy
- Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
- Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
- Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
- Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases
- Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
- Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- Study of Screening Brain MRIs in Stage IV Breast Cancer
- Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
- The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)